Back to top
more

Endo International plc (ENDP)

(Delayed Data from NSDQ)

$8.20 USD

8.20
3,004,238

+0.48 (6.22%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark

by Zacks Equity Research

Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.

Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More

by Zacks Equity Research

Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) is set to report earnings and revenues, and provide updates on its diversified product portfolio when it releases third-quarter 2021 results.

Endo International (ENDP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why the Earnings Surprise Streak Could Continue for Endo (ENDP)

by Zacks Equity Research

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Endo (ENDP) Gains on Settlement of Opioid Cases in New York for $50M

by Zacks Equity Research

Endo (ENDP) stock gains following the settlement of three opioid cases in the New York State in exchange for a total payment of $50 million.

BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold

by Zacks Equity Research

BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.

Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

Endo International (ENDP) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Endo (ENDP) delivered earnings and revenue surprises of 54.76% and 8.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Endo International (ENDP) Q2 Earnings Expected to Decline

by Zacks Equity Research

Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1

by Zacks Equity Research

Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.

Endo International (ENDP) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Endo (ENDP) delivered earnings and revenue surprises of 52.08% and 7.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why the Earnings Surprise Streak Could Continue for Endo (ENDP)

by Zacks Equity Research

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Is Endo (ENDP) Down 16.8% Since Last Earnings Report?

by Zacks Equity Research

Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4

by Zacks Equity Research

Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.

Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.

Can Endo (ENDP) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why Momentum Investors Will Love Endo International (ENDP)

by Zacks Equity Research

Does Endo International (ENDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Radius (RDUS) to Acquire Rights for Cannabidiol Oral Solution

by Zacks Equity Research

Radius (RDUS) is set to acquire the global development and commercialization rights of Benuvia Therapeutics' synthetic cannabidiol oral solution for utilization in multiple endocrine and metabolic orphan diseases.

Radius (RDUS) Inks Deal for Tymlos in Canada With Paladin Labs

by Zacks Equity Research

Radius (RDUS) signs an agreement with Paladin Labs, wherein the latter will now be responsible for all commercial activities related to Tymlos and abaloparatide-TD in Canada.

Why Is Endo (ENDP) Up 10.5% Since Last Earnings Report?

by Zacks Equity Research

Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Can Value Investors Pick Endo International (ENDP) Stock ?

by Zacks Equity Research

Is Endo International (ENDP) a great pick from the value investor's perspective right now? Read on to know more.

Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised

by Zacks Equity Research

Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.